Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock, tax-free merger of equals, creating a diversified CNS-focused biopharmaceutical company with approximately $2.2 billion in combined annual revenues.
The combined company will be named Supernus, Inc., listed on the Nasdaq under ticker "SUPN", and led by Supernus CEO Jack Khattar as President and CEO, with Indivior’s Tony Kingsley as Board Chair.
The transaction is expected to close in the fourth quarter of 2026, is subject to regulatory and shareholder approvals, and is projected to deliver about $125 million in annual cost synergies and expand business development opportunities in the CNS and neuroscience space.
Sources:
Supernus and Indivior merge to create CNS mega- ...
Supernus, Indivior merge to strengthen neuroscience drug ...
Supernus Shares Jump After Revenue Beat, Higher ...
CNS-focused Supernus and Indivior agree merger terms
Indivior and Supernus in $2.2B CNS merger | INDV 8-K Filing
Supernus, Indivior merge to strengthen neuroscience drug ...
Supernus Pharmaceuticals, Inc.'s Post